Nanoparticle Delivery
Nanoparticle Delivery - Related Videos
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
0 Views •
Cited by 49 •
2016
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
08:51
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
0 Views •
Cited by 9 •
2013
A protocol for nanoparticle tracking analysis (NTA) and high-throughput flow cytometry to evaluate polymeric gene delivery nanoparticles is described. NTA is utilized to characterize the nanoparticle particle size distribution and the plasmid per particle distribution. High-throughput flow cytometry enables quantitative transfection efficacy evaluation for a library of gene delivery biomaterials.
01:33
Nanoparticle-Mediated Enhanced Delivery of an Anti-Inflammatory Drug in Microglia-Like Cells
0 Views •
2025
Take cultures of human monocyte-derived microglia-like cells.Introduce nanoparticles containing an anti-inflammatory drug into the experimental culture and the free drug into the control.The nanoparticles feature a hydrophilic shell and a hydrophobic core encapsulating the lipophilic drug.The cells endocytose the nanoparticles, which release the drug intracellularly, enhancing its delivery.The free drug enters by passive diffusion, a process constrained by the concentration gradient, which...
01:28
Focused Ultrasound-Enhanced Nanoparticle Delivery in a Mouse Model for Tumor Therapy
0 Views •
2025
Begin with an anesthetized tumor-bearing mouse and shave its head.Place it in an MRI scanner integrated with the focused ultrasound system.The initial MRI scan locates the brain tumor and nearby blood vessels.Inject a contrast agent intravenously, then administer fluorescently labeled nanoparticles coated onto gas-filled microbubbles.The contrast agent and microbubbles circulate and reach the brain.Apply focused ultrasound waves to the tumor site.The ultrasound causes the microbubbles to expand...
10:16
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
0 Views •
Cited by 3 •
2017
A liquid crystal nanoparticle (LCNP) nanocarrier is exploited as a vehicle for the controlled delivery of a hydrophobic cargo to the plasma membrane of living cells.
FAQs
Particle size, composition, surface chemistry, and release behavior jointly shape where a therapeutic travels and how it becomes available. These features influence circulation, tissue distribution, cellular uptake, and cargo release rather than acting independently. Consequently, clinical formulation design must balance delivery to selected tissues with the desired timing and location of therapeutic exposure.
The carrier’s interaction with its cargo depends on whether the therapeutic is encapsulated or bound. That distinction is relevant because the platform must accommodate chemically different payloads, including small-molecule drugs, proteins, and nucleic acids. In clinical research, matching carrier properties to cargo can support protection of fragile molecules and maintain delivery performance.
A carrier can protect a therapeutic during circulation, but clinical value also depends on how the cargo is released after reaching its intended setting. Release properties therefore connect formulation design with cellular uptake and therapeutic availability. Researchers consider them when seeking more controlled exposure and reduced off-target effects than conventional formulations may provide.
Clinical research applies nanoparticle delivery across cancer treatment, vaccination, and gene-based therapies, but the rationale differs by therapeutic challenge. The approach can help protect fragile therapeutics, reduce off-target exposure, and improve pharmacokinetics. These goals make it relevant when treatment effectiveness depends on where a molecule travels, how long it remains available, or how safely it reaches cells.
Evaluation focuses on the delivery chain from circulation to intracellular availability. Researchers can examine how formulation choices affect circulation, tissue distribution, cellular uptake, and eventual cargo release. These outcomes help connect physical carrier properties with pharmacokinetics and with the practical goal of limiting exposure outside the intended tissue.
Development requires linking the carrier’s physical and chemical design with the therapeutic’s behavior in the body. Materials science informs composition, surface chemistry, and release properties, while pharmacology provides context for circulation, tissue distribution, cellular uptake, and pharmacokinetics. This combined perspective supports formulations intended for diseases that conventional approaches may be difficult to target.